albuterol has been researched along with Innate Inflammatory Response in 72 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
| Excerpt | Relevance | Reference |
|---|---|---|
| "BACKGROUND The aim of this study was to evaluate the therapeutic effects of tiotropium bromide on asthma." | 9.27 | Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma. ( Han, S; Huang, G; Jin, L; Zhang, L, 2018) |
| "Fourteen atopic patients with mild-to-moderate asthma (forced expiratory volume in 1 second of 76%) completed a double-blind, randomized, crossover study consisting of 3-week treatment blocks of either fluticasone propionate-salmeterol, 250 microg twice daily, or fluticasone propionate alone, 250 microg twice daily, in conjunction with either fexofenadine, 180 mg once daily, or matched placebo." | 9.11 | Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. ( Fardon, TC; Hodge, MR; Lee, DK; Lipworth, BJ, 2005) |
| "The aim of this study was to test the hypothesis that the addition of the long-acting beta(2)-agonist salmeterol (SALM) to a low dose of the inhaled corticosteroid fluticasone propionate (FP) has a steroid-sparing effect and does not result in a worsening of bronchial inflammation compared to doubling the dose of inhaled corticosteroid." | 9.10 | Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. ( Bjermer, L; Djukanović, R; Holgate, S; Lindberg, A; Lundbäck, B; Sandström, T; Sue-Chu, M; Wallin, A; Ward, J; Wilson, S, 2003) |
| "Results indicated quercetin to be a better prophylactic that augmented AFC in rats exposed to hypoxia by attenuating inflammation and stimulating β2-AR." | 7.96 | Efficacy of Quercetin as a potent sensitizer of β2-AR in combating the impairment of fluid clearance in lungs of rats under hypoxia. ( Kaur, P; Kumar, B; Kumar, M; Sagi, SSK; Tripathi, A, 2020) |
| "A subset of patients with chronic obstructive pulmonary disease (COPD) may respond more favorably to inhaled corticosteroids (ICS), but no simple method is currently utilized to predict the presence or absence of ICS responses in patients with COPD." | 6.73 | Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study. ( Janoff, EN; Kunisaki, KM; Niewoehner, DE; Rector, TS; Rice, KL, 2008) |
| " Whether inhaled corticosteroids by themselves or in combination with a long-acting beta2-adrenoceptor agonist repress systemic inflammation in chronic obstructive pulmonary disease is unknown." | 6.72 | Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. ( Cowie, RL; FitzGerald, M; Ford, G; Mainra, RR; Man, SF; Marciniuk, DD; Melenka, LS; Ramesh, W; Rousseau, R; Sin, DD; Wilde, E; Williams, D; Wong, E; York, E, 2006) |
| "Before and after each course of treatment, airway inflammation was assessed via exhaled nitric oxide breath testing." | 6.72 | Randomized placebo controlled assessment of airway inflammation due to racemic albuterol and levalbuterol via exhaled nitric oxide testing. ( Allan, PF; Arora, R; Freiler, JF; Hagan, L; Kelley, TC, 2006) |
| "Inflammation was observed in the intestinal mucosa of mice in the AAD group." | 5.62 | Colonic Mucosal Immune Activation in Mice with Ovalbumin-Induced Allergic Airway Disease: Association between Allergic Airway Disease and Irritable Bowel Syndrome. ( Byun, J; Choi, H; Chun, H; Jeen, Y; Keum, B; Kim, B; Kim, E; Kim, S; Kim, T; Lee, H; Lee, J; Lee, K; Yeon, J, 2021) |
| "BACKGROUND The aim of this study was to evaluate the therapeutic effects of tiotropium bromide on asthma." | 5.27 | Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma. ( Han, S; Huang, G; Jin, L; Zhang, L, 2018) |
| "Results confirm the antioxidant dose- and time-dependent activity of erdosteine, and support the utility of including erdosteine it in the therapeutic strategy for the prevention and treatment of oxidative stress-induced inflammation, which frequently leads to AECOPD occurrence." | 5.20 | Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial. ( Dal Negro, RW; Turco, P; Visconti, M, 2015) |
| "Intravenous salbutamol (albuterol) reduces lung water in patients with the acute respiratory distress syndrome (ARDS)." | 5.12 | In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injury. ( Gao, F; McAuley, DF; Nathani, N; Perkins, GD; Thickett, DR, 2007) |
| "Fourteen atopic patients with mild-to-moderate asthma (forced expiratory volume in 1 second of 76%) completed a double-blind, randomized, crossover study consisting of 3-week treatment blocks of either fluticasone propionate-salmeterol, 250 microg twice daily, or fluticasone propionate alone, 250 microg twice daily, in conjunction with either fexofenadine, 180 mg once daily, or matched placebo." | 5.11 | Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. ( Fardon, TC; Hodge, MR; Lee, DK; Lipworth, BJ, 2005) |
| "The aim of this study was to test the hypothesis that the addition of the long-acting beta(2)-agonist salmeterol (SALM) to a low dose of the inhaled corticosteroid fluticasone propionate (FP) has a steroid-sparing effect and does not result in a worsening of bronchial inflammation compared to doubling the dose of inhaled corticosteroid." | 5.10 | Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. ( Bjermer, L; Djukanović, R; Holgate, S; Lindberg, A; Lundbäck, B; Sandström, T; Sue-Chu, M; Wallin, A; Ward, J; Wilson, S, 2003) |
| "Results indicated quercetin to be a better prophylactic that augmented AFC in rats exposed to hypoxia by attenuating inflammation and stimulating β2-AR." | 3.96 | Efficacy of Quercetin as a potent sensitizer of β2-AR in combating the impairment of fluid clearance in lungs of rats under hypoxia. ( Kaur, P; Kumar, B; Kumar, M; Sagi, SSK; Tripathi, A, 2020) |
| " Thus, our study assessed the effects of salmeterol, fluticasone, and montelukast on human epithelial lung cell inflammation as well as the inhibitors in different signal transduction pathways." | 3.75 | Asthma drugs counter-regulate interleukin-8 release stimulated by sodium sulfite in an A549 cell line. ( Chu, JJ; Fu, LS; Hsu, JY; Weng, YS; Yang, YF, 2009) |
| " We have investigated the effects of RP 73401, a novel, potent and highly selective cyclic nucleotide phosphodiesterase (PDE) type IV inhibitor, in guinea-pig and rat models of bronchoconstriction and allergic inflammation." | 3.69 | Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. ( Battram, CH; Jordan, R; Lewis, SA; Raeburn, D; Sharma, S; Souness, JE; Tomkinson, A; Underwood, SL; Webber, SE; Woodman, VR, 1994) |
| "After discontinuation of the treatment, cough scores increased, pulmonary function and eosinophilic airway inflammation were aggravated and returned to the baseline levels." | 2.80 | Effects of regular treatment with combination of salmeterol/fluticasone propionate and salmeterol alone in cough variant asthma. ( Kawagoe, M; Kirishi, S; Kondo, M; Kubota, N; Tagaya, E; Tamaoki, J, 2015) |
| "A total of 72 patients with type 2 diabetes were randomized to receive NCB-02 (two capsules containing curcumin 150 mg twice daily), atorvastatin 10 mg once daily or placebo for 8 weeks." | 2.73 | Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. ( Chandra, N; Mateen, AA; Naidu, MU; Raju, YS; Usharani, P, 2008) |
| "A subset of patients with chronic obstructive pulmonary disease (COPD) may respond more favorably to inhaled corticosteroids (ICS), but no simple method is currently utilized to predict the presence or absence of ICS responses in patients with COPD." | 2.73 | Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study. ( Janoff, EN; Kunisaki, KM; Niewoehner, DE; Rector, TS; Rice, KL, 2008) |
| "Various lung diseases are associated with local activation of coagulation and concurrent inhibition of fibrinolysis." | 2.73 | Salmeterol enhances pulmonary fibrinolysis in healthy volunteers. ( Bresser, P; de Vos, AF; Jansen, HM; Levi, M; Maris, NA; van der Poll, T; van der Zee, JS, 2007) |
| " Whether inhaled corticosteroids by themselves or in combination with a long-acting beta2-adrenoceptor agonist repress systemic inflammation in chronic obstructive pulmonary disease is unknown." | 2.72 | Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. ( Cowie, RL; FitzGerald, M; Ford, G; Mainra, RR; Man, SF; Marciniuk, DD; Melenka, LS; Ramesh, W; Rousseau, R; Sin, DD; Wilde, E; Williams, D; Wong, E; York, E, 2006) |
| "Before and after each course of treatment, airway inflammation was assessed via exhaled nitric oxide breath testing." | 2.72 | Randomized placebo controlled assessment of airway inflammation due to racemic albuterol and levalbuterol via exhaled nitric oxide testing. ( Allan, PF; Arora, R; Freiler, JF; Hagan, L; Kelley, TC, 2006) |
| "Airway inflammation was assessed 24 h after the AC by bronchoalveolar lavage (BAL) (n = 16) and bronchial biopsies (n = 13)." | 2.70 | Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma. ( Boulet, LP; Boutet, M; Chakir, J; Laviolette, M; Milot, J, 2001) |
| "Airway inflammation is a key factor in the mechanisms of asthma." | 2.42 | Mechanisms of asthma. ( Busse, WW; Rosenwasser, LJ, 2003) |
| "Inflammation was observed in the intestinal mucosa of mice in the AAD group." | 1.62 | Colonic Mucosal Immune Activation in Mice with Ovalbumin-Induced Allergic Airway Disease: Association between Allergic Airway Disease and Irritable Bowel Syndrome. ( Byun, J; Choi, H; Chun, H; Jeen, Y; Keum, B; Kim, B; Kim, E; Kim, S; Kim, T; Lee, H; Lee, J; Lee, K; Yeon, J, 2021) |
| "When roflumilast was evaluated, the addition of salmeterol (1 nM) to roflumilast caused the IC50 for roflumilast to shift from 1." | 1.38 | Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells. ( Haran, AC; Mansfield, CN; Salmon, M; Sorensen, EA; Tannheimer, SL; Wright, CD, 2012) |
| "COPD is a disease with a multi-component pathophysiology in which inflammation plays a key role." | 1.35 | Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. ( Agusti, AG; Barnes, NC; Johnson, M, 2008) |
| ") completely reversed the rightward shift of the formoterol dose-response curve due to beta(2)-receptor desensitisation." | 1.34 | Formoterol and beclomethasone dipropionate interact positively in antagonising bronchoconstriction and inflammation in the lung. ( Bergamaschi, M; Berti, F; Bolzoni, P; Civelli, M; Razzetti, R; Rossoni, G; Villetti, G, 2007) |
| "Pulmonary inflammation was induced in adult Wistar rats by a 60-min exposure to endotoxin (lipopolysaccharide, LPS, 100 micrograms/mL)." | 1.30 | Effects of interleukin-10 and modulators of cyclic AMP formation on endotoxin-induced inflammation in rat lung. ( Boichot, E; Escofier, N; Germain, N; Lagente, V; Martins, MA; Silva, PM, 1999) |
| " We conclude that sputum induction using a relatively low output ultrasonic nebulizer with premedication with salbutamol is successful and safe in the majority of patients with asthma and other airway conditions." | 1.30 | The safety and success rate of sputum induction using a low output ultrasonic nebuliser. ( Hunter, CJ; Pavord, ID; Ward, R; Wardlaw, AJ; Woltmann, G, 1999) |
| " Before salmeterol treatment was initiated and after 3, 6, 9 and 12 months of salmeterol treatment, a cumulative dose-response curve to inhaled salbutamol (100, 300 and 900 micrograms) was performed, and FEV1 measured." | 1.28 | Twelve months, treatment with inhaled salmeterol in asthmatic patients. Effects on beta 2-receptor function and inflammatory cells. ( Lötvall, J; Lunde, H; Svedmyr, N; Törnqvist, H; Ullman, A, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (6.94) | 18.7374 |
| 1990's | 16 (22.22) | 18.2507 |
| 2000's | 30 (41.67) | 29.6817 |
| 2010's | 18 (25.00) | 24.3611 |
| 2020's | 3 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, S | 1 |
| Keum, B | 1 |
| Byun, J | 1 |
| Kim, B | 1 |
| Lee, K | 1 |
| Yeon, J | 1 |
| Lee, J | 1 |
| Choi, H | 1 |
| Kim, E | 1 |
| Jeen, Y | 1 |
| Lee, H | 1 |
| Chun, H | 1 |
| Kim, T | 1 |
| Tripathi, A | 1 |
| Kumar, M | 1 |
| Kaur, P | 1 |
| Kumar, B | 1 |
| Sagi, SSK | 1 |
| Higaki, N | 1 |
| Iwamoto, H | 1 |
| Yamaguchi, K | 1 |
| Sakamoto, S | 1 |
| Horimasu, Y | 1 |
| Masuda, T | 1 |
| Miyamoto, S | 1 |
| Nakashima, T | 1 |
| Ohshimo, S | 1 |
| Fujitaka, K | 1 |
| Hamada, H | 1 |
| Hattori, N | 1 |
| Mukherjee, M | 1 |
| Cingolani, E | 1 |
| Pritchard, DI | 1 |
| Bosquillon, C | 1 |
| Rossi, SP | 1 |
| Walenta, L | 1 |
| Rey-Ares, V | 1 |
| Köhn, FM | 1 |
| Schwarzer, JU | 1 |
| Welter, H | 1 |
| Calandra, RS | 1 |
| Frungieri, MB | 1 |
| Mayerhofer, A | 1 |
| Zhang, L | 1 |
| Huang, G | 1 |
| Jin, L | 1 |
| Han, S | 1 |
| Ravi, A | 1 |
| Chowdhury, S | 1 |
| Dijkhuis, A | 1 |
| Bonta, PI | 1 |
| Sterk, PJ | 2 |
| Lutter, R | 1 |
| Akamatsu, T | 1 |
| Shirai, T | 1 |
| Kato, M | 1 |
| Yasui, H | 1 |
| Hashimoto, D | 1 |
| Fujisawa, T | 1 |
| Tsuchiya, T | 1 |
| Inui, N | 1 |
| Suda, T | 1 |
| Chida, K | 1 |
| Popov, TA | 1 |
| Petrova, D | 1 |
| Kralimarkova, TZ | 1 |
| Ivanov, Y | 1 |
| Popova, T | 1 |
| Peneva, M | 1 |
| Odzhakova, T | 1 |
| Ilieva, Y | 1 |
| Yakovliev, P | 1 |
| Lazarova, T | 1 |
| Georgiev, O | 1 |
| Hodzhev, V | 1 |
| Hodzheva, E | 1 |
| Staevska, MT | 1 |
| Dimitrov, VD | 1 |
| Hatchwell, L | 1 |
| Girkin, J | 1 |
| Dun, MD | 1 |
| Morten, M | 1 |
| Verrills, N | 1 |
| Toop, HD | 1 |
| Morris, JC | 1 |
| Johnston, SL | 1 |
| Foster, PS | 1 |
| Collison, A | 1 |
| Mattes, J | 1 |
| Ozogul, B | 1 |
| Halici, Z | 2 |
| Cadirci, E | 2 |
| Karagoz, E | 1 |
| Bayraktutan, Z | 1 |
| Yayla, M | 1 |
| Akpinar, E | 1 |
| Atamanalp, SS | 1 |
| Unal, D | 1 |
| Karamese, M | 1 |
| Tagaya, E | 1 |
| Kondo, M | 1 |
| Kirishi, S | 1 |
| Kawagoe, M | 1 |
| Kubota, N | 1 |
| Tamaoki, J | 1 |
| Boudewijn, IM | 1 |
| Postma, DS | 2 |
| Telenga, ED | 1 |
| Ten Hacken, NH | 2 |
| Timens, W | 2 |
| Oudkerk, M | 1 |
| Ross, BD | 1 |
| Galbán, CJ | 1 |
| van den Berge, M | 1 |
| Dal Negro, RW | 1 |
| Visconti, M | 1 |
| Turco, P | 1 |
| Denlinger, LC | 1 |
| Phillips, BR | 1 |
| Ramratnam, S | 1 |
| Ross, K | 1 |
| Bhakta, NR | 1 |
| Cardet, JC | 1 |
| Castro, M | 1 |
| Peters, SP | 1 |
| Phipatanakul, W | 1 |
| Aujla, S | 1 |
| Bacharier, LB | 1 |
| Bleecker, ER | 1 |
| Comhair, SA | 1 |
| Coverstone, A | 1 |
| DeBoer, M | 1 |
| Erzurum, SC | 1 |
| Fain, SB | 1 |
| Fajt, M | 1 |
| Fitzpatrick, AM | 1 |
| Gaffin, J | 1 |
| Gaston, B | 1 |
| Hastie, AT | 1 |
| Hawkins, GA | 1 |
| Holguin, F | 1 |
| Irani, AM | 1 |
| Israel, E | 1 |
| Levy, BD | 1 |
| Ly, N | 1 |
| Meyers, DA | 1 |
| Moore, WC | 1 |
| Myers, R | 1 |
| Opina, MT | 1 |
| Peters, MC | 1 |
| Schiebler, ML | 1 |
| Sorkness, RL | 1 |
| Teague, WG | 1 |
| Wenzel, SE | 2 |
| Woodruff, PG | 1 |
| Mauger, DT | 1 |
| Fahy, JV | 1 |
| Jarjour, NN | 1 |
| Usharani, P | 1 |
| Mateen, AA | 1 |
| Naidu, MU | 1 |
| Raju, YS | 1 |
| Chandra, N | 1 |
| Kunisaki, KM | 1 |
| Rice, KL | 1 |
| Janoff, EN | 1 |
| Rector, TS | 1 |
| Niewoehner, DE | 1 |
| Perng, DW | 1 |
| Tao, CW | 1 |
| Su, KC | 1 |
| Tsai, CC | 1 |
| Liu, LY | 1 |
| Lee, YC | 1 |
| Johnson, M | 3 |
| Agusti, AG | 1 |
| Barnes, NC | 1 |
| Yang, YF | 1 |
| Hsu, JY | 1 |
| Fu, LS | 1 |
| Weng, YS | 1 |
| Chu, JJ | 1 |
| Borrill, Z | 1 |
| Roy, K | 1 |
| Kolsum, U | 1 |
| Southworth, T | 1 |
| Vestbo, J | 1 |
| Singh, D | 1 |
| Lapperre, TS | 1 |
| Snoeck-Stroband, JB | 1 |
| Gosman, MM | 1 |
| Jansen, DF | 1 |
| van Schadewijk, A | 1 |
| Thiadens, HA | 1 |
| Vonk, JM | 1 |
| Boezen, HM | 1 |
| Sont, JK | 1 |
| Rabe, KF | 1 |
| Kerstjens, HA | 1 |
| Hiemstra, PS | 1 |
| Puckett, JL | 1 |
| Taylor, RW | 1 |
| Leu, SY | 1 |
| Guijon, OL | 1 |
| Aledia, AS | 1 |
| Galant, SP | 1 |
| George, SC | 1 |
| Hozawa, S | 1 |
| Terada, M | 1 |
| Hozawa, M | 1 |
| Ciprandi, G | 1 |
| Signori, A | 1 |
| Cirillo, I | 1 |
| Khianey, R | 1 |
| Oppenheimer, J | 2 |
| Tannheimer, SL | 1 |
| Sorensen, EA | 1 |
| Haran, AC | 1 |
| Mansfield, CN | 1 |
| Wright, CD | 1 |
| Salmon, M | 1 |
| Uzkeser, H | 1 |
| Odabasoglu, F | 1 |
| Polat, B | 1 |
| Yuksel, TN | 1 |
| Ozaltin, S | 1 |
| Atalay, F | 1 |
| Wolf, BL | 1 |
| Busse, WW | 1 |
| Rosenwasser, LJ | 1 |
| Wallin, A | 1 |
| Sue-Chu, M | 1 |
| Bjermer, L | 1 |
| Ward, J | 1 |
| Sandström, T | 1 |
| Lindberg, A | 1 |
| Lundbäck, B | 1 |
| Djukanović, R | 1 |
| Holgate, S | 1 |
| Wilson, S | 1 |
| Lipworth, BJ | 2 |
| Jackson, CM | 1 |
| Devillier, P | 1 |
| Agrawal, DK | 1 |
| Ariyarathna, K | 1 |
| Kelbe, PW | 1 |
| Gelb, AF | 1 |
| Taylor, CF | 1 |
| Nussbaum, E | 1 |
| Gutierrez, C | 1 |
| Schein, A | 1 |
| Shinar, CM | 1 |
| Schein, MJ | 1 |
| Epstein, JD | 1 |
| Zamel, N | 1 |
| Currie, GP | 1 |
| Lee, DK | 2 |
| Fardon, TC | 1 |
| Hodge, MR | 1 |
| Tanaka, S | 1 |
| Yamagishi, R | 1 |
| Tsutsui, M | 1 |
| Kishida, T | 1 |
| Murakami, M | 1 |
| Kuroda, J | 1 |
| Yoshida, T | 1 |
| Sin, DD | 1 |
| Man, SF | 1 |
| Marciniuk, DD | 1 |
| Ford, G | 1 |
| FitzGerald, M | 1 |
| Wong, E | 1 |
| York, E | 1 |
| Mainra, RR | 1 |
| Ramesh, W | 1 |
| Melenka, LS | 1 |
| Wilde, E | 1 |
| Cowie, RL | 1 |
| Williams, D | 1 |
| Rousseau, R | 1 |
| Goldman, CA | 1 |
| Robinson, EM | 1 |
| Goldman, MD | 1 |
| Perkins, GD | 1 |
| Nathani, N | 1 |
| McAuley, DF | 1 |
| Gao, F | 1 |
| Thickett, DR | 1 |
| Maris, NA | 1 |
| de Vos, AF | 1 |
| Bresser, P | 1 |
| van der Zee, JS | 1 |
| Jansen, HM | 1 |
| Levi, M | 1 |
| van der Poll, T | 1 |
| Razzetti, R | 1 |
| Bergamaschi, M | 1 |
| Villetti, G | 1 |
| Bolzoni, P | 1 |
| Civelli, M | 1 |
| Berti, F | 1 |
| Rossoni, G | 1 |
| Nelson, HS | 1 |
| Freiler, JF | 1 |
| Arora, R | 1 |
| Kelley, TC | 1 |
| Hagan, L | 1 |
| Allan, PF | 1 |
| Ferrada, MA | 1 |
| Gordon, EL | 1 |
| Jen, KY | 1 |
| He, HZ | 1 |
| Lu, X | 1 |
| Barone, LM | 1 |
| Amirifeli, S | 1 |
| Perkins, DL | 1 |
| Finn, PW | 1 |
| Basran, GS | 1 |
| Paul, W | 1 |
| Morley, J | 2 |
| Turner-Warwick, M | 1 |
| Raeburn, D | 1 |
| Underwood, SL | 1 |
| Lewis, SA | 1 |
| Woodman, VR | 1 |
| Battram, CH | 1 |
| Tomkinson, A | 1 |
| Sharma, S | 1 |
| Jordan, R | 1 |
| Souness, JE | 1 |
| Webber, SE | 1 |
| Tang, CB | 1 |
| Quan, BW | 1 |
| Wang, XF | 1 |
| Xiong, YX | 1 |
| Wu, GH | 1 |
| Kraft, M | 1 |
| Bettinger, CM | 1 |
| Martin, RJ | 1 |
| Dykewicz, MS | 1 |
| Ledford, DK | 1 |
| Escofier, N | 1 |
| Boichot, E | 1 |
| Germain, N | 1 |
| Silva, PM | 1 |
| Martins, MA | 1 |
| Lagente, V | 1 |
| Costello, J | 1 |
| Handley, D | 1 |
| Hunter, CJ | 1 |
| Ward, R | 1 |
| Woltmann, G | 1 |
| Wardlaw, AJ | 1 |
| Pavord, ID | 1 |
| Li, X | 1 |
| Ward, C | 1 |
| Thien, F | 1 |
| Bish, R | 1 |
| Bamford, T | 1 |
| Bao, X | 1 |
| Bailey, M | 1 |
| Wilson, JW | 1 |
| Haydn Walters, E | 1 |
| Boulet, LP | 1 |
| Chakir, J | 1 |
| Milot, J | 1 |
| Boutet, M | 1 |
| Laviolette, M | 1 |
| Naedele-Risha, R | 1 |
| Dorinsky, P | 1 |
| Craig, TJ | 1 |
| McDonald, DM | 1 |
| Baramki, D | 1 |
| Koester, J | 1 |
| Anderson, AJ | 1 |
| Borish, L | 1 |
| Lampa, E | 1 |
| Apolito, A | 1 |
| Russo, G | 1 |
| Pedone, P | 1 |
| Alise, G | 1 |
| Seely, RJ | 1 |
| Glenn, EM | 1 |
| Dry, J | 1 |
| Spring, J | 1 |
| Johnston, SR | 1 |
| Seale, J | 1 |
| Ind, PW | 1 |
| Lötvall, J | 1 |
| Lunde, H | 1 |
| Ullman, A | 1 |
| Törnqvist, H | 1 |
| Svedmyr, N | 1 |
| Morice, AH | 1 |
| Butchers, PR | 1 |
| Vardey, CJ | 1 |
| Norris, AA | 1 |
| Leeson, ME | 1 |
| Jackson, DM | 1 |
| Holroyde, MC | 1 |
| Beusenberg, FD | 1 |
| Adolfs, MJ | 1 |
| Van Schaik, A | 1 |
| Van Amsterdam, JG | 1 |
| Bonta, IL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Severe Asthma Research Program (SARP) - University of Wisconsin[NCT01760915] | 107 participants (Actual) | Observational | 2012-11-28 | Completed | |||
| Anti-inflammatory Effects of Tiotropium in Patients With Stable COPD- A Multicenter Randomized Controlled Double-blind Study[NCT04061161] | Phase 4 | 50 participants (Anticipated) | Interventional | 2019-08-19 | Recruiting | ||
| Responsivity and Reproducibility of Messenger and Micro RNA Airway Inflammatory Markers - a Pilot Study[NCT03924843] | 21 participants (Actual) | Observational | 2017-11-14 | Completed | |||
| A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered[NCT00268216] | Phase 3 | 6,228 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| Modification of Disease Outcome in COPD. Shortterm Versus Longterm Treatment With Inhaled Corticosteroids, Either or Not Combined With a Long-Acting Beta2-Agonist.[NCT00158847] | Phase 4 | 200 participants | Interventional | 2000-04-30 | Terminated | ||
| Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol on Peripheral Airway Function in Asthma Patients[NCT02415179] | 52 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| Evaluation of Additive Effects of Zileuton to Advair on Total Exhaled, Bronchial, and Alveolar Nitric Oxide in Asthmatics[NCT00575861] | Phase 4 | 19 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers[NCT01225913] | Phase 4 | 50 participants (Anticipated) | Interventional | 2007-10-31 | Recruiting | ||
| Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers[NCT00576069] | 60 participants (Anticipated) | Observational | 2007-10-25 | Recruiting | |||
| Advair - CRP Study[NCT00120978] | Phase 4 | 250 participants | Interventional | 2004-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for albuterol and Innate Inflammatory Response
| Article | Year |
|---|---|
Controversies regarding long-acting β2-agonists.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Albuterol; Anti-Asthmatic Agents; Asth | 2011 |
Mechanisms of asthma.
Topics: Adenine; Adult; Albuterol; Asthma; Bronchodilator Agents; Chemokines; Child; Cytokines; Disease Prog | 2003 |
[Physiopathology of COPD: choosing the right therapeutic targets].
Topics: Adrenal Cortex Hormones; Aged; Albuterol; Animals; Bacterial Infections; Bronchodilator Agents; Carb | 2003 |
Something old, something new, something borrowed. COPD treatment today.
Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Anti-Inflammatory Agents; Beclomethasone; Br | 2006 |
Safety of long-acting beta-agonists in asthma: a review.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adrenergic | 2008 |
Beta 2-agonists as anti-inflammatory therapies in the lung.
Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchitis; Ca | 1993 |
Anomalous effects of albuterol and other sympathomimetics in the guinea pig.
Topics: Albuterol; Animals; Bronchial Hyperreactivity; Drug Hypersensitivity; Guinea Pigs; Inflammation; Rec | 1996 |
Recent findings in asthma likely to impact patient care.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Gastroesophageal Reflux; Humans; | 1998 |
Prospects for improved therapy in chronic obstructive pulmonary disease by the use of levalbuterol.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Inflammation; Lung Disea | 1999 |
The asthma-like pharmacology and toxicology of (S)-isomers of beta agonists.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchi; Bronchoconstriction; Bronchodilator A | 1999 |
Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long-acting beta-agonists with inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi | 2001 |
23 trials available for albuterol and Innate Inflammatory Response
| Article | Year |
|---|---|
Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma.
Topics: Adult; Albuterol; Asthma; Cholinergic Antagonists; Female; Humans; Inflammation; Interleukin-13; Mal | 2018 |
Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Androstadie | 2014 |
Real life clinical study design supporting the effectiveness of extra-fine inhaled beclomethasone/formoterol at the level of small airways of asthmatics.
Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anti-Inflammato | 2013 |
Effects of regular treatment with combination of salmeterol/fluticasone propionate and salmeterol alone in cough variant asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Asthma; Bronc | 2015 |
Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
Topics: Administration, Oral; Adult; Aged; Albuterol; Antioxidants; Bronchodilator Agents; Dose-Response Rel | 2015 |
Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations.
Topics: Adolescent; Adult; Albuterol; Asthma; Biomarkers; Body Mass Index; Breath Tests; Bronchodilator Agen | 2017 |
Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Atorvastatin; Biomarkers; Blood Glucose; Cholesterol; Cu | 2008 |
Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study.
Topics: Administration, Inhalation; Aged; Albuterol; Androstadienes; Biomarkers; Bronchodilator Agents; C-Re | 2008 |
Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Biomarkers; C | 2009 |
Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Biomarkers; C | 2009 |
Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Biomarkers; C | 2009 |
Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Biomarkers; C | 2009 |
Seretide withdrawal increases airway inflammation in moderate COPD patients.
Topics: Aged; Airway Obstruction; Albuterol; Androstadienes; Drug Combinations; Fluticasone-Salmeterol Drug | 2009 |
Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.
Topics: Administration, Inhalation; Aged; Albuterol; Androstadienes; Bronchi; Bronchodilator Agents; Cell Co | 2009 |
Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma.
Topics: Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Budesonide; Drug Combinations; Etha | 2011 |
Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Asthma; Biopsy; Bronchi; Double-Blind | 2003 |
Effects of salmeterol on smooth muscle versus inflammatory outcomes.
Topics: Albuterol; Androstadienes; Asthma; Cross-Over Studies; Drug Therapy, Combination; Fluticasone; Human | 2003 |
Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma.
Topics: Adenosine Monophosphate; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Alb | 2005 |
Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Androstadienes; Anti-Inflammatory Agents; Bronch | 2006 |
In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injury.
Topics: Albuterol; Bronchoalveolar Lavage Fluid; Bronchodilator Agents; Double-Blind Method; Enzyme-Linked I | 2007 |
Salmeterol enhances pulmonary fibrinolysis in healthy volunteers.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Bronch | 2007 |
Randomized placebo controlled assessment of airway inflammation due to racemic albuterol and levalbuterol via exhaled nitric oxide testing.
Topics: Adrenergic beta-Agonists; Aged; Aged, 80 and over; Albuterol; Exhalation; Female; Humans; Inflammati | 2006 |
The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Proteins; Bronchoalveolar Lavage Fluid; Br | 1997 |
An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anti-Inflammatory Agents | 1999 |
Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma.
Topics: Adolescent; Adult; Albuterol; Allergens; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-B | 2001 |
Failure of salmeterol to inhibit circulating white cell responses and bronchoconstriction induced by platelet activating factor.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Bronchoconstriction; Double-Blind Method; Female; Humans | 1992 |
38 other studies available for albuterol and Innate Inflammatory Response
| Article | Year |
|---|---|
Colonic Mucosal Immune Activation in Mice with Ovalbumin-Induced Allergic Airway Disease: Association between Allergic Airway Disease and Irritable Bowel Syndrome.
Topics: Administration, Intranasal; Albuterol; Animals; Disease Models, Animal; Inflammation; Intestinal Muc | 2021 |
Efficacy of Quercetin as a potent sensitizer of β2-AR in combating the impairment of fluid clearance in lungs of rats under hypoxia.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Antioxidants; Body Fluids; Cyclic AMP-Depen | 2020 |
Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Inflammation; Oscillometry; Spirometry | 2021 |
Enhanced expression of Organic Cation Transporters in bronchial epithelial cell layers following insults associated with asthma - Impact on salbutamol transport.
Topics: Albuterol; Allergens; Asthma; Biological Transport; Bronchi; Bronchodilator Agents; Cell Culture Tec | 2017 |
Alpha 1 adrenergic receptor-mediated inflammatory responses in human testicular peritubular cells.
Topics: Adrenergic alpha-1 Receptor Agonists; Albuterol; Cell Survival; Chemokine CCL2; Drug Inverse Agonism | 2018 |
Neutrophilic inflammation in asthma and defective epithelial translational control.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchial Hyperreactiv | 2019 |
Salmeterol attenuates chemotactic responses in rhinovirus-induced exacerbation of allergic airways disease by modulating protein phosphatase 2A.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Antigens, Dermatophagoides; Chemotaxis; Dis | 2014 |
Comparative study on effects of nebulized and oral salbutamol on a cecal ligation and puncture-induced sepsis model in rats.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-2 Receptor Agonists; Albuterol; An | 2015 |
Effects of ageing and smoking on pulmonary computed tomography scans using parametric response mapping.
Topics: Adult; Aging; Albuterol; Algorithms; Female; Forced Expiratory Volume; Humans; Inflammation; Linear | 2015 |
Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients.
Topics: Albuterol; Androstadienes; Anti-Inflammatory Agents; Bronchodilator Agents; Drug Combinations; Fluti | 2008 |
Asthma drugs counter-regulate interleukin-8 release stimulated by sodium sulfite in an A549 cell line.
Topics: Acetates; Air Pollutants; Albuterol; Androstadienes; Anti-Asthmatic Agents; Cell Line; Cell Survival | 2009 |
Summaries for patients. Effect of treatment with fluticasone with and without salmeterol on airway inflammation and lung function in patients with chronic obstructive pulmonary disease: a randomized trial.
Topics: Administration, Inhalation; Aged; Albuterol; Androstadienes; Bronchodilator Agents; Drug Administrat | 2009 |
An elevated bronchodilator response predicts large airway inflammation in mild asthma.
Topics: Adolescent; Albuterol; Asthma; Biomarkers; Breath Tests; Bronchodilator Agents; California; Child; E | 2010 |
Relationship between bronchial hyperreactivity and bronchodilation in patients with allergic rhinitis.
Topics: Adult; Albuterol; Asthma; Bronchi; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchodi | 2011 |
Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Aminopyridines; Anti-Inflammatory Agents; Benzamides | 2012 |
Anti-inflammatory and antinociceptive effects of salbutamol on acute and chronic models of inflammation in rats: involvement of an antioxidant mechanism.
Topics: Albuterol; Animals; Anti-Inflammatory Agents; Carrageenan; Edema; Glutathione; Hyperalgesia; Inflamm | 2012 |
The current landscape of asthma: a new geometry.
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchial Hyperreactivity; Drug Combinatio | 2002 |
(S)-Albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Albuterol; Bronchi; Calcium; Cells, Cultured; Colforsin | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
The GOAL study: designed to favor a long-acting beta2-agonist?
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchial Hyperr | 2005 |
Tissue- and dose-dependent alteration of stress-inducible proteins by beta2-adrenoceptor agonist, salbutamol, in rats.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-2 Receptor Antagonists; Albuterol; Animals; Cyt | 2005 |
Formoterol and beclomethasone dipropionate interact positively in antagonising bronchoconstriction and inflammation in the lung.
Topics: Acetylcholine; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Animals; An | 2007 |
(R)-albuterol decreases immune responses: role of activated T cells.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Cell Line; Cells, Cultured; Disease Models, Animal; Eo | 2008 |
Adrenoceptor-agonist inhibition of the histamine-induced cutaneous response in man.
Topics: Adult; Albuterol; Female; Histamine; Histamine Antagonists; Humans; Inflammation; Male; Middle Aged; | 1982 |
Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor.
Topics: Albuterol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Bronchial Hyperreactivity; | 1994 |
Influence of airway inflammatory changes on airway hyperresponsiveness in asthmatics.
Topics: Adult; Albuterol; Asthma; Beclomethasone; Bronchial Hyperreactivity; Bronchial Provocation Tests; Br | 1993 |
Effects of interleukin-10 and modulators of cyclic AMP formation on endotoxin-induced inflammation in rat lung.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Animals; Bronchoalveolar Lavage Flu | 1999 |
The safety and success rate of sputum induction using a low output ultrasonic nebuliser.
Topics: Adolescent; Adult; Aged; Albuterol; Bronchodilator Agents; Cell Count; Female; Forced Expiratory Vol | 1999 |
Angiogenesis and remodeling of airway vasculature in chronic inflammation.
Topics: Adrenergic beta-Antagonists; Adult; Albuterol; Angiopoietin-1; Animals; Asthma; Bronchitis; Bronchod | 2001 |
Modulation of T-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer.
Topics: Adrenergic beta-Agonists; Albuterol; Apoptosis; Cell Line; Cytokines; Humans; Inflammation; Interleu | 2002 |
[Specific and aspecific activity of an antihistaminic of the H1 type: HC 20-511 or ketothiphen (benzo-cyclohepta-thiophenone derivative)].
Topics: Albuterol; Anaphylaxis; Animals; Anura; Bronchial Spasm; Cardiovascular System; Chlorpheniramine; Do | 1977 |
Salbutamol as a topical anti-inflammatory drug.
Topics: Administration, Topical; Albuterol; Animals; Anti-Inflammatory Agents; Dermatitis; Ear; Edema; Hydro | 1978 |
[The therapeutic year].
Topics: Albuterol; Anti-Inflammatory Agents; Aspirin; Calcitonin; Colchicine; Drug Therapy; Endocrine System | 1976 |
Twelve months, treatment with inhaled salmeterol in asthmatic patients. Effects on beta 2-receptor function and inflammatory cells.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Blood Platelet | 1992 |
A European respiratory review on salmeterol.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchi; Humans; Inflammation; Salmeterol Xinafoate | 1991 |
Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung.
Topics: Adrenergic beta-Agonists; Albuterol; Histamine Release; Humans; Hypersensitivity; In Vitro Technique | 1991 |
Modulation of neurogenic inflammation in rat trachea.
Topics: Albuterol; Animals; Cromolyn Sodium; Dexamethasone; Electric Stimulation; Inflammation; Male; Methys | 1990 |
Antigen challenge modifies the cyclic AMP response of inflammatory mediators and beta-adrenergic drugs in alveolar macrophages.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Animals; Antigens; Bronchoalveolar | 1989 |